Inactive

Synopsis for "Oncotype Dx" Genetic Breast Cancer Testing.: This is a combined Sole Source Synopsis / Solicitation published for informational purposes only. This proposed action is for genetic testing... Synopsis for "Oncotype Dx" Genetic Breast Cancer Testing.: This is a combined Sole Source Synopsis / Solicitation published for informational purposes only. This proposed action is for genetic testing for breast cancer known as "Oncotype Dx" assay for the Medical Treatment Facility (88 MDSS/SGSM) located at Wright-Patterson AFB, OH. See Attachment 1, Statement of Work. The Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b)(1). This proposed procurement will be a Sole Source under North American Industry Classification System Code (NAICS) 621511: Medical Laboratories. Business size standard for NAICS 334516 is $32,500,000.00. PSC/FSC code: Q301: MEDICAL - LABORATORY TESTING. The proposed source is Genomic Health, Inc., located at 301 Penobscot Dr. Redwood City, CA, 94063-4700. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. This notice of intent is not a request for competitive quotations. However, all responsible sources may submit a capability statement, proposal, quotation or exception to the intent to purchase on a sole source basis, which shall be considered by the Government, if received by Thursday, 14 February 2019, 2:00 P.M. EST. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to comply with FAR 5.207(c)(15), the reason for lack of competition is as follows: The Government requires genetic testing for breast cancer known as "Oncotype Dx" assay for the Medical Treatment Facility (88 MDSS/SGSM) located at Wright-Patterson AFB, OH. The proposed sole source, Genomic Health, is the only known source able to provide the "Oncotype Dx" Assay. Delivery Schedule: As scheduled following award Delivery Destination: 88 MDSS/SGSM Attn: Ms. Mary Kathy Carey 4881 Sugar Maple Drive Wright-Patterson AFB, OH 45433 Delivery Type: FOB Destination (As defined in FAR 2.101 - Definitions, the seller or consignor is responsible for the cost of shipping and risk of loss.) Inspection and Acceptance: Both inspection and acceptance will be by the Government at Destination. Important Notice to Contractors: All prospective awardees are required to register at the System for Award Management (SAM) and to maintain active registration during the life of the contract. SAM can be accessed at https://www.sam.gov. For a detailed description of the applicable SAM requirements and payment information, please review the clauses included in the attached solicitation. Any information should be e-mailed to both elizabeth.moles@us.af.mil and casey.macpherson@us.af.mil no later than Thursday, 14 February 2019, 2:00 P.M. EST. Only inquiries/information received through e-mail by this date will be considered. Please be advised that all correspondence sent via e-mail shall contain a subject line that reads "Oncotype Dx Genetic Breast Cancer Testing". Note that e-mail filters at Wright-Patterson AFB are designed to filter e-mails without subject lines or with suspicious subject lines or contents (i.e., .exe, or .zip files). Therefore, if this subject line is not included, the e-mail may not get through the e-mail filters. Also be advised that .zip or .exe files are not allowable attachments and may be deleted by the e-mail filters at Wright-Patterson Air Force Base. If sending attachments with e-mail ensure only .PDF, .doc, or .xls documents are sent. The e-mail filter may delete any other form of attachments.